Zytiga – practice-changing clinical news but is it a home run?

ASCO provided practice-changing news for prostate cancer patients – Zytiga (abiraterone) added to standard hormone therapy in newly diagnosed high risk metastatic patients reduces the chance of death...
Learn More

The Wisdom of Henri Termeer, 1946-2017

What Can We Learn?   Henri Termeer, one of the founding fathers of biopharma, died last week leaving a superb legacy of achievement in the industry. Always a colourful figure, some of his most...
Learn More

Colin Miller, medical imaging consultant, presents poster at OARSI meeting

Medical imaging expert and Alacrita Partner, Colin G Miller PhD, presented his poster titled "Standardization of imaging reads for eligibility assessment of patients — Component of a risk mitigation...
Learn More

BIO-Europe 2017: Clinical trials in Early Stage Oncology Development

Recently, I was fortunate enough to moderate a provocative panel on clinical trials in early stage oncology development at the BIO-Europe Spring meeting in Barcelona (19-22 March, 2017)
Learn More

Healthcare Rationing or Simply Prioritization?

An interesting paper by Roland Turck (doi:10.1093/annonc/mdw548) puts oncology drug pricing into a certain perspective. For me, the most perceptive remark is that while oncology drugs represent only...
Learn More

EMA solution for the post-Brexit era

Here's an idea: designate the EMA's location in Canary Wharf as sovereign EU territory (just as if it were an embassy) and then it could remain in London yet still be located in the EU...
Learn More

Post EMA approval: how soon can products be sold?

Question: After EMA approval, are sales of a pharmaceutical allowed in EU5, before pricing is approved? What is the soonest a company can sell a pharmaceutical agent in Europe after approval?
Learn More